Murat Albayrak

Dışkapı Yıldırım Beyazıt Training and Research Hospital, Engüri, Ankara, Turkey

Are you Murat Albayrak?

Claim your profile

Publications (20)14.14 Total impact

  • Esra Can Sarıbacak · Harika Okutan · Murat Albayrak · Han Unsal

    No preview · Article · Jan 2016
  • [Show abstract] [Hide abstract]
    ABSTRACT: Multiple myeloma (MM) is a disease of the geriatric population with a median age at diagnosis of 69 years but most clinicians consider performance status and comorbidities rather than chronological age in determining prognosis and treatment. The purpose of this study was to assess whether and which comorbidity indices predict survival in a real life population of MM. We calculated Charlson Comorbidity Index (CCI), age combined Charlson index (CCI-age), Hematopoietic cell transplantation-specific comorbidity index (HCT-SCI) and Freiburger comorbidity index (FCI) retrospectively for 66 MM patients and compared their impact on treatment responses and overall survival (OS). Treatment response was significantly worse in groups with high CCI, CCI-age, HCT-SCI scales (p < 0.05), but FCI’s effect on treatment response was not significant. However, while no significant relationship was determined between other comorbidity indices with OS, it was related only with FCI–CI (p = 0.006). FCI, developed in this patient group, was the only prognostic index with a significant effect on OS in the evaluation of comorbidities in MM patients with different scores, but its relationship to treatment responses was not significant contrary to other indices. While this small patient group gave us hope regarding the use of FCI in practice, multi-center studies are still required.
    No preview · Article · Nov 2015 · Indian Journal of Hematology and Blood Transfusion
  • Source

    Preview · Article · Dec 2014 · The Turkish journal of gastroenterology: the official journal of Turkish Society of Gastroenterology
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to establish the protective effect of caffeic acid phenethyl ester (CAPE) against the ifosfamide (IFOS)-induced central neurotoxicity in rats and to determine the changes in oxidant-antioxidant status of brain tissue. Method: A total of 35 Wistar rats (aged 7-12 days) were used in the experiments. The study comprised of five groups. Control untreated rats (n = 7) belonged to group 1; group 2 was given intraperitoneal (IP) injection of CAPE alone (10 µmol/kg; n = 7); group 3 was treated with single IP injection of IFOS (500 mg/kg; n = 7); group 4 was treated for 2 days with IP administration of CAPE (10 µmol/kg) beginning from one day before single IP injection of IFOS (n = 7); and group 5 was treated with saline and 10% ethanol. At the 24th hour of IFOS treatment, brain tissues were removed for analysis. The brain catalase activity was lower in IFOS group than the other groups (p < 0.05). The levels of malondialdehyde (MDA) and protein carbonyl content in brain tissue were higher in IFOS group than the control, CAPE, ethanol, and IFOS + CAPE groups (p < 0.05). There was no significant difference between MDA and protein carbonyl content of control, CAPE, ethanol, and IFOS + CAPE groups. Immunohistochemistry showed marked activation of caspase 3 in the IFOS group at 24 h after treatment. This study revealed that pretreatment with CAPE might protect brain tissue against IFOS-induced central neurotoxicity. CAPE could be an effective course of therapy to enhance therapeutic efficacy and to lessen IFOS toxicity in clinical chemotherapy.
    No preview · Article · Oct 2013 · Toxicology and Industrial Health
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Angiotensin converting enzyme (ACE) is a circulating enzyme that participates in the body's renin-angiotensin system (RAS) and is localized on the endothelial cell surface in the lung and other vascular beds. It catalyses the conversion of decapeptide angiotensin I to octapeptide angiotensin II. In the present study, we aimed to analyse the possible relationship between the levels of ACE in the context of RAS in multiple myeloma (MM) pathogenesis. The study was conducted on 25 MM patients (13 males, 12 females; median age 66 years, range 47-88) and 20 healthy controls. The clinical features of MM patients including demographics and laboratory findings were summarized. Serum ACE levels were measured by using commercially available kits. The serum ACE levels of MM patients and controls were 32.60±20.26 and 15.35±6.47 respectively. Serum ACE levels were significantly higher in MM patients compared with control groups (p<0.001). Being an important component of RAS, circulating ACE might be associated with clonal proliferation of malignant plasma cells in the bone marrow microenvironment. Identification of the pathobiological activity of the local RAS in MM would enlighten the biologic basis and clinical management of haematologic disorders.
    Full-text · Article · Feb 2012 · Journal of Renin-Angiotensin-Aldosterone System
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: AIM: In addition to suppressing fibrinolysis, thrombin activatable fibrinolysis inhibitor (TAFI) was suggested to be involved in inflammation. To date, no study has been published that reports the role of TAFI in acute pancreatitis (AP). Therefore, the objective of the present study was to investigate the role of plasma TAFI as an indicator of inflammation in AP, and its association with disease severity. METHODS: Plasma TAFI antigen levels quantitatively determined by using ELISA kits in 21 AP patients at onset and remission and 17 healthy controls. Associations of TAFI with inflammatory markers to determine AP and disease severity were assessed. To predict the severity of AP, modified Glasgow prognostic score (mGPS) and computerized tomography severity index (CTSI) were used for each subject. RESULTS: Plasma TAFI levels was higher in AP patients at onset of the disease compared with healthy controls. The disease severity according to mGPS was significantly correlated with TAFI levels. Overall, accuracy of TAFI in determining AP was 83.3% with a sensitivity, specificity, NPV and PPV of 80.9%, 85.7%, 81.8%, and 85% respectively (AUC: 0.915). CONCLUSIONS: The present study for the first time demonstrated that TAFI is elevated in AP. The appraisal of TAFI levels in patients with AP in conjunction with other markers of inflammation may provide additional information in estimating AP severity.
    Full-text · Article · Jan 2012 · Gastroentérologie Clinique et Biologique

  • No preview · Article · Dec 2011 · Acta gastro-enterologica Belgica
  • [Show abstract] [Hide abstract]
    ABSTRACT: Imatinib mesylate (STI 571) is one of the fundamental chemotherapeutic agents used in the treatment of the chronic, accelerated and blastic phases of chronic myelocytic leukemia (CML), gastrointestinal stromal tumors and Philadelphia chromosome-positive acute lymphoblastic leukemia. It selectively inhibits receptor tyrosine kinases. Its effects limit the use of this drug. We present a case with a serious skin reaction requiring the discontinuation of the drug and that developed in relation to imatinib therapy. Six months prior, a 61-year-old male patient presenting to the hematology polyclinic with complaints of weight loss and sweating was hospitalized due to high leukocyte value. As a result of the hemogram, biochemistry analyses, peripheral blood smear examination, bone marrow aspiration evaluation, cytogenetic examination using FISH and PCR that were performed, CML was diagnosed. Additionally, to exclude myelofibrosis, we examined a bone marrow biopsy. Imatinib mesylate was started at 400 mg/day orally. In the fourth month of treatment, the patient complained of itching and a skin rash. Although the drug dose was reduced (300 mg/day), his complaints gradually increased. The skin biopsy result was superficial perivascular dermatitis. Imatinib was discontinued, and the patient was started on corticosteroid. The lesions disappeared completely. A month later, the patient was restarted on imatinib mesylate. However, the lesions recurred more prominently. His itching increased. The patient was considered intolerant to imatinib mesylate, and a second-generation tyrosine kinase inhibitor, dasatinib 100 mg/day, was started orally. The follow-up and treatment continues for the patient, who has been taking dasatinib 100 mg/day for the last two months without any skin finding or complaints. Imatinib mesylate-induced skin reactions are associated with the pharmacologic effect of the drug rather than hypersensitivity to the drug. Skin reactions are frequently observed, and this side effect is dose dependent. However, the interesting aspect of our case was that despite dose reduction, skin findings gradually increased, and eventually the drug had to be discontinued.
    No preview · Article · Dec 2011 · Eurasian Journal of Medicine

  • No preview · Article · Jun 2011 · Pathology & Oncology Research
  • [Show abstract] [Hide abstract]
    ABSTRACT: Multiple myeloma has been associated with the development of thromboembolic events. Thrombin activatable fibrinolysis inhibitor (TAFI) is a carboxypeptidase B-like proenzyme, which potently inhibits fibrinolysis. The purpose of the present study was to assess the TAFI levels in patients with newly diagnosed multiple myeloma. Twenty-seven newly diagnosed multiple myeloma patients (16 women and 11 men) and 27 age-matched healthy individuals (14 women and 13 men) were included in the study. Serum TAFI levels were significantly increased in patients with multiple myeloma (46 ± 13. 3 vs. 36. 6 ± 9.7 μg/ml) compared with healthy individuals. Serum TAFI levels were negatively correlated with serum albumin (CC: -0.453, P < 0.05) and hemoglobin levels (CC: -0.392, P < 0.05) and positively correlated with the β-2 microglobulin levels (CC: 0.524, P < 0.05). In this study, we observed significantly elevated TAFI levels in patients with multiple myeloma and higher serum TAFI levels were suggested to be associated with higher disease stage. With these results, a possible role of elevated TAFI levels in thromboembolic manifestations in the course of multiple myeloma can be suggested.
    No preview · Article · Feb 2011 · Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In this case report we overview the diagnostic and therapeutic approaches for pleural effusions encountered during the tre-atment and follow-up of patients with myeloma in the light of the current medical literature. A 73-year-old female patient with a stage IIIA multiple myeloma was being treated with melphalan and methyl prednisolone. In the third month of the treat-ment, she had complaints of coughing, dyspnea and right side pain. Computed tomographic examination of the thorax re-vealed pleural effusion. Pathological examinations of the pleural fluid and pleural biopsy specimen were compatible with ade-nocarcinoma. Repeated examinations did not reveal a progression in myeloma or a pleural involvement of myeloma. The pa-tient died of respiratory insufficiency due to the progression of the pleural adenocarcinoma.
    Preview · Article · Jan 2011 · UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi
  • M. Albayrak · H. Celebi · V. Aslan · E.S. Can · B. Onec · B.U. Koluman · D. Tatar
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To evaluate the thrombophilic risk factors and incidence in patients presenting at the hematology outpatient clinic for further investigation after the diagnosis of pulmonary embolism. Methodology: A total of 15 cases (8 male, 7 female) with the diagnosis of pulmonary embolism and referred to hematology clinic for investigating thrombophilic risk factors were retrospectively evaluated. Thrombophilic screening tests for these patients are as follows: factor V leiden (FVL), prothrombin G20210 A (PTG) and methylentetrahydrofolate reductase (MTHFR C677 T) gene mutations, protein C (PC), protein S (PS) and antithrombin III (AT III) deficiency, active protein C resistance (APC-R), antinuclear antibodies (ANA), anti dsDNA, anticardiolipin antibodies IgM and IgG, lupus anticoagulant, homocysteine and factor VIII levels were investigated. Results: The commonest thrombophilic defect was MTHFR C677T gene mutation (n=12) (80%). Single defect (n=4) was found at a rate of 26.6%, double defects (n=2) 13.3%, triple defects (n=5) 33.3% and four defects (n=3) 20%. One patient had no defects. Conclusion: In this retrospective study carried out in patients with pulmonary embolism, MTHFR gene mutation was found to be the commonest cause for hereditary thrombophilia as a single risk factor and/or together with other thrombophilic risk factors.
    No preview · Article · Jan 2011
  • Source
    Simten Dagdas · Gulsum Ozet · Mesude Yilmaz · Murat Albayrak · Funda Ceran
    [Show abstract] [Hide abstract]
    ABSTRACT: In this study, we evaluated the plasma levels of endostatin (PE) and its prognostic importance in patients with acute myeloblastic (AML) and lypmhoblastic leukemia (ALL). We therefore analyzed plasma levels of endostatin before the chemotherapy and during the complete remission period in adult ALL and AML patients. The PE levels of the control group were significantly lower than both cases with ALL and AML. The patients with AML during remission had significantly higher PE levels than the levels at initial diagnosis. No statistically significant difference was detected in patients with ALL. In addition, the survival rates of the cases with ALL whose PE levels are higher than 2.5 ng/ml, are significantly lower. Our results suggest that the elevated plasma levels of endostatin during the remission in patients with AML imply the intensity of angiogenesis inhibition during the remission. Furthermore our findings in ALL patients suggest that endostatin levels may predict the overall survival of these patients.
    Preview · Article · Jan 2011 · UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi
  • Osman Yokus · Ozlem Sahin Balcik · Murat Albayrak
    [Show abstract] [Hide abstract]
    ABSTRACT: Vitamin B12 deficiency may cause hematologic, gastrointestinal, psychiatric and neurological symptoms. Sub-acute combined degeneration of spinal cord, which develops in the deficiency of vitamin B12, may be reversible in case of early diagnosis and treatment. We describe the management of a 50-years old female who got admitted with pancytopenia and elevated LDH, with walking difficulties since last 15 days. B12 and folic acid levels were found in normal ranges. Megaloblastic changes were observed in the bone marrow examination. Abnormal hyperintence signal changes were observed in T2-weighed cervical spinal cord Magnetic Resonance Imaging in posterior row. Due to the high homocysteine level, treatment with parenteral B12 vitamin was initiated. Following the 3-months treatment, hematologic counts and neurological symptoms of the patient were found to be completely recovered at the control visit. Vitamin B12 deficiency should be considered for the patients with pancytopenia, elevated LDH levels and neurological symptoms, even if vitamin B12 and MCV levels are in normal ranges. Vitamin B12 deficiency should be confirmed with the additional assays, such as, the assessment of serum homocysteine and methylmalonic acid levels, and the treatment should be started promptly.
    No preview · Article · Jul 2010 · Pakistan Journal of Medical Sciences Online
  • [Show abstract] [Hide abstract]
    ABSTRACT: The increased risk for thrombosis is known as hypercoagulability or thrombophilia. Here, we investigated risk factors for thrombophilia which were screened in young adult patients presenting with thrombotic events or with recurrent abortions with unknown etiology. A total of 115 patients aged between 16 and 50 years who were found to harbor thrombophilia were retrospectively evaluated. The laboratory investigations performed for the assessment of thrombophilia included protein C, protein S, antithrombin III deficiencies, activated protein C resistance, factor V Leiden (FVL), prothrombin 20210A (PT 20210) and methylenetetrahydrofolate reductase (MTHFR) gene mutations, factor VIII elevation, lupus anticoagulant and antiphospholipid antibodies (APA). In 66% of the cases a single thrombophilic defect was identified while some of the patients had combined thrombophilic defects. The most common thrombophilic defect was mutation in the MTHFR gene, and was followed by FVL mutation, the presence of APA and PT 20210 gene mutation, respectively. The patients were divided into two different age groups, 16-35 and 36-50 years, and arterial thrombosis was more common in the older age group. Our results indicated that some important thrombophilic defects such as gene mutations may appear in young adult patients presenting with thrombotic events.
    No preview · Article · Nov 2009 · International journal of hematology
  • S. Daǧdaş · M. Albayrak · O.S. Balçik · G. Özet · F. Ceran · S. Erekul
    [Show abstract] [Hide abstract]
    ABSTRACT: Castleman's disease is a rare lymphoproliferative disease which is morphologically and clinically heterogeneous. His-topathologically it is classified into hyaline vascular, plasma cell and mixed variants and clinically into unicentric and multicentric types. Although it presents with diverse clinical and laboratory findings, as far as we know, there is no case in the literature that presents with such a marked lympho-cytosis which can simulate chronic lymphocytic leukemia. In this report, a case of Castleman's disease, that is HHV-8 positive multicentric hyaline vascular type and displaying marked lymphocytosis is presented.
    No preview · Article · Jan 2009 · Turkish Journal of Cancer
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Although regimens of harvesting peripheric stem cell vary from one center to another, the most common ones are growth factor plus chemotherapy or growth factor alone. In our study, we aimed to determine which regimens of harvesting peripheral stem cell are more effective on the number of CD34(+) cells. Material and Methods: Between March 2004 and June 2007, sixty six cases included in the autologous peripheral stem cell harvesting program in the Ankara Numune Hospital Bone Marrow Transplantation Unit were evaluated retrospectively. They were diagnosed with Hodgkin's disease, non Hodgkin lymphoma, multiple myeloma, and testis germ cell tumor. Regarding harvesting regimes, 41 cases were administered cyclophosphamid + etoposide + filgrastim 5 μg/kg/day (CEF), 7 cases cyclophosphamid + filgrastim 5 μg/kg./day (CF), and 18 cases filgrastim 10 μg/kg/day (F). Results: In the CEF, CF, and F groups, the median duration of filgrastim treatment before harvesting CD34(+) cells was 9, 10 and 5 days respectively. The difference was statistically significant between CEF-F and CF-F groups in terms of the duration of filgrastim treatment before harvesting CD34(+) cells (p< 0.01). The median number of CD34(+) cell apheresis was 1, 2, 2 in the CEF, CF, and F groups, respectively. The difference between the CEF and F groups (p> 0.001) regarding the number of apheresis was allso significant. In the CEF, CF, and F groups, the median number of harvested CD34(+) cells were 7.36 × 106/kg, 3.4 × 106/kg, and 4.1 × 106/kg respectively; the difference between the CEF-CF and CEF-F groups was statistically significant (p= 0.004 and p< 0.001). Conclusion: Higher number of CD34(+) cells can be harvested with the CEF regimen compared to the CF and F regimens. Filgrastim 10 μg/kg/day could harvest an adequate number of CD34(+) cells despite the requirement for more apheresis procedures. The effect of harvesting regimens on engrafment will be evaluated later in our center.
    No preview · Article · Oct 2008 · Turkiye Klinikleri Journal of Medical Sciences
  • [Show abstract] [Hide abstract]
    ABSTRACT: B-cell chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) are chronic B cell malignancies originating from different phases of B cell development. They are rarely seen together. A 64 year-old male diagnosed with CLL was being followed up, bone marrow biopsy were performed after the devolopment of hyperglobulinemia and increased serum urea values. Bone marrow biopsy revealed an increase of 40% atypical plasma cell count and 35% lymphocyte count. Although no alkylating agent was used, additional development of MM clone to CLL is remarkable. This situation was seen very rarely in the literature. We aimed to present this case to be an instrument in the understanding of B cell oncogenesis in molecular level.
    No preview · Article · Jan 2008 · UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Ankaferd Blood Stopper (ABS) is a novel topical hemostatic agent. ABS-induced formation of the protein network with vital erythro-id aggregation covers the entire physiological hemostatic process. ABS has pleiotropic cellular, proteomic, transcriptomic, and me-tabolomic effects. ABS also affects the expression of important hemostatic molecules namely PAR-1, EPCR and PAI-1. The aim of this study was to detect the macroscopic, biochemical, and cytopathological effects of ABS on myeloma monoclonal immunoglo-bulin (M-protein). Based on our results, the addition of ABS into the serum of both multiple myeloma (MM) and control groups resul-ted in significantly decrements in the level of total protein, albumin, IgG, IgA and IgM. Furthermore, the decrements in the MM pati-ents were more pronounced than in the healthy control subjects. ABS has a potential role in decreasing of serum proteins and mo-noclonal M-proteins. Moreover, the declining in the neoplastic monoclonal M-protein was more prominent. We hypothesized that ABS could be used as an "agglutination-controlling factor" for myeloma monoclonal proteins and the protein-aggregating effects of ABS may be helpful for expressing the regulatory molecules promoting or preventing the myeloma protein aggregation. ÖZET Ankaferd Hemostat ile ‹n Vitro Myelom Monoklonal ‹mmünglobulin Agregasyonunun Belirgin Art›fl› Ankaferd Blood Stopper (ABS) yeni bir topikal hemostatic ajand›r. ABS taraf›ndan indüklenen protein a¤› oluflumu hayati eritroid ag-regasyonu ile birlikte tüm fizyolojik hemostatik süreci kapsar. ABS hücresel pleiotropik, proteomik, transkriptomik ve metabolik etki-lere sahiptir. ABS ayn› zamanda PAR-1, EPCR ve PAI-1 gibi önemli hemostatik moleküllerin ekspresyonunu da etkiler. Bu çal›flma-n›n amac›; ABS'nin miyelom monoklonal immünoglobulini (M-protein) üzerindeki makroskopik, biyokimyasal ve sitopatolojik etkilerini saptamakt›. Sonuçlar›m›za göre, hem multiple myelom (MM) hem de kontrol gruplar›n›n serumlar›na ABS ilavesi total protein, albu-min, IgG, IgA ve IgM seviyelerinde belirgin bir azalmayla sonuçland›. Ek olarak, MM hastalar›nda görülen azalma sa¤l›k-l› kontrol grubundakilerden daha belirgindi. ABS serum proteinlerinin ve monoklonal M-proteinlerinin azalmas›nda potansiyel bir role sahiptir. Ayr›ca neoplastik monoklonal M-proteinlerindeki azalma daha da belirgindi. Hipotezimize göre, ABS miyelom monoklonal proteini için ''agglütinasyonu control eden faktör''olarak kullan›labilir ve ABS'nin proteinleri aglütine edici etkisi, miyelom protein ag-regasyonunu önleyen veya artt›ran düzenleyici moleküllerin ekspresyonunda yard›mc› olabilir.
    Full-text · Article · Jan 1999
  • Source

    Full-text · Article ·

Publication Stats

24 Citations
14.14 Total Impact Points

Institutions

  • 2012
    • Dışkapı Yıldırım Beyazıt Training and Research Hospital
      Engüri, Ankara, Turkey
  • 2011
    • Ankara Numune Training and Research Hospital
      Engüri, Ankara, Turkey
  • 1999-2011
    • Ankara Children's Hematology Oncology Training and Research Hospital
      Engüri, Ankara, Turkey
  • 2008
    • Ankara University
      Engüri, Ankara, Turkey